Amylyx said last month it was considering pulling its drug Relyvrio after a clinical trial in 600 patients failed to show any improvements in survival or other health measures. The maker of the drug has now announced that it will voluntarily halt sales and marketing of the drug, acknowledging its lack of effectiveness in helping patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of its drug for Lou Gehrig’s disease, acknowledging it didn't help patients with the deadly neurological condition . Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
Amylyx Pharmaceuticals Drug Lou Gehrig’S Disease Clinical Trial Patients Sales Marketing Effectiveness Neurological Condition
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Amylyx May Pull FDA-Approved ALS Drug After Failed Phase 3 TrialTopline results for the ALS drug Relyvrio show that it failed to meet primary or secondary endpoints. The company says it may voluntarily pull the drug from the market.
Read more »
Amylyx Ditches Controversial ALS Drug RelyvrioAfter disappointing phase 3 trial results in ALS, Amylyx will pull Relyvrio from the market but provide it free to patients who want to stay on the medication.
Read more »
Why Amylyx is pulling ALS drug Relyvrio from US market after studyThe maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market. Amylyx Pharmaceuticals said Thursday it will halt marketing in the U.S. and Canada. In March, the drugmaker announced that its drug had failed to show any benefit for patients in a 600-person study.
Read more »
The Future of Pharmaceuticals: How AI is Transforming Drug DiscoveryAI is changing the game in drug development! Exscientia's breakthrough in treating an 82-year-old's resistant blood cancer shows how personalized treatments and faster discoveries are now within reach.
Read more »
Controversial ALS Drug May Be Pulled from Market After Disappointing Trial ResultsFollowing disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market. Amylyx Pharmaceuticals is considering voluntarily withdrawing the drug, Relyvrio/Albrioza, after it failed to help patients in a large follow-up study. The company has decided to pause promotion of the medication and will announce their plans for the drug in the next two months.
Read more »
Is a "human escape velocity" even possible anymore?As LLMs pull us towards a cognitive singularity, can we escape AI's irresistible pull?
Read more »